Daclizumab Has Winning Efficacy In MS, But Safety Questions Linger
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Top-line results from a Phase IIb trial of Biogen Idec Inc./Abbott Laboratories Inc.'s daclizumab in relapsing-remitting multiple sclerosis are impressive, but data from an ongoing Phase III trial may clear up lingering questions about the drug's safety profile.
You may also be interested in...
Energized Biogen Idec On Track For Two Filings In 2012
Biogen hopes to submit marketing applications in the U.S. and Europe for both MS therapy BG-12 and its therapies for hemophilia A and B in 2012, with launches possible in early and mid-2013.
Disappointing BRAVO Data Raise Doubts About Laquinimod’s Chances
Teva Pharmaceuticals Co. Ltd. is facing investor doubts about regulatory prospects for its oral multiple sclerosis drug laquinimod after the drug missed the primary endpoint in a second Phase III trial, called BRAVO.
Disappointing BRAVO Data Raise Doubts About Laquinimod’s Chances
Teva Pharmaceuticals Co. Ltd. is facing investor doubts about regulatory prospects for its oral multiple sclerosis drug laquinimod after the drug missed the primary endpoint in a second Phase III trial, called BRAVO.